Navigation Links
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Date:8/19/2009

otease inhibitor compound RG7227/ ITMN-191 in Phase 2b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors disc
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Rochester Medical Reports Third Quarter Results
2. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
5. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
6. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
7. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
8. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
9. Rochester Medical Corporation Set to Join Russell 3000 Index
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... GoDaddy, IX Web Hosting and Bluehost are ... Server) hosting, which is the method of partitioning ... of which has the appearance and capabilities of ... recently compared many professional web hosting suppliers and ... VPS hosting suppliers in the global market. , ...
(Date:8/31/2014)... Mesa, Arizona (PRWEB) August 31, 2014 For ... ragweed is likely the culprit. Ragweed is the most common ... percent of Americans. , The most common symptoms of ragweed ... and throat, and sneezing. Ragweed allergy can also lead to ... ragweed allergies should consult an allergist about allergy immunotherapy - ...
(Date:8/31/2014)... 01, 2014 In order to celebrate the ... announced its latest designs and launched a big promotion. Now, ... , All the company’s new cars are made with ... for the global customers. As a matter of fact, it ... items. Those who are in need of cheap cars can ...
(Date:8/31/2014)... LabDoor.com tests the purity and label accuracy of ... website, “We buy products in the same fashion as ... sites. No manufacturer-supplied samples are permitted at LabDoor.” As ... a recent study was performed on twenty of the ... States for Vitamin D3 content, heavy metal contamination, and ...
(Date:8/31/2014)... 2014 In the wake of growing ... proposed legislation to require mandatory labeling of GMOs on ... purchasing decisions that affect their own health and the ... for stringent measures to eliminate GMOs from dietary supplements, ... Engagement” (I.C.E.) initiative with the objective of advancing the ...
Breaking Medicine News(10 mins):Health News:GoDaddy, IX Web Hosting and Bluehost Are Awarded As Hosting Experts by Top10BestSEOHosting.com 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 2Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 4Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3
... , , ... Reportlinker.com announces that a new market research report is available ... Endoscopy Devices , , http://www.reportlinker.com/p0131252/Gastrointestinal-Endoscopy-Devices.html ... market for Gastrointestinal Endoscopy Devices in Millions of US$ analyzed by ...
... , Rx Bottles Filled with ... Fix Broken System Upon His Return to Washington ... Members of Congress have just returned to Washington D.C. after their ... to make reforming health care a top priority. With a giant ...
... Economic slump encourages more people ... Vancouver, ... more Canadians are making the decision to head back to school to re-train, instead of waiting ... Canada, has seen a dramatic spike in enrollments in 2009. Between July 2008 and July 2009, ...
... , , ... San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a ... National Institute of Allergy and Infectious Disease (National Institutes of Health) ... H5N1 Avian influenza. , , "We thank ...
... ECCO 15 ESMO 34 will take place at ... D-14055 Berlin, Germany ( www.icc-berlin.de ) from Sunday 20 ... be more than 2,000 presentations and over 15,000 participants ... congress to date. The congress will discuss the ...
... , ATLANTA, Sept. 8 Renowned ... Coke, in collaboration with the American Dietetic Association (ADA) are providing ... Tastefully campaign will feature pop-up kitchens in midtown Manhattan and Boston, ... are all a part of living well. , , ...
Cached Medicine News:Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 2Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 3Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 4Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 5Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 6Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 7Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 8Health News:Fall 2009 Sees Spike in Enrollments at CDI College 2Health News:Vaxart Awarded NIH Grant to Support Development of Orally-Delivered H5N1 Avian Influenza Vaccine 2Health News:Media registration for ECCO 15 -- ESMO 34 multidisciplinary cancer congress 2Health News:Media registration for ECCO 15 -- ESMO 34 multidisciplinary cancer congress 3Health News:Video: Eat Tastefully Campaign: Diet Coke, Renowned Chef, Pop-Up Kitchen Reveal Secrets to Great Taste, Living Well 2Health News:Video: Eat Tastefully Campaign: Diet Coke, Renowned Chef, Pop-Up Kitchen Reveal Secrets to Great Taste, Living Well 3Health News:Video: Eat Tastefully Campaign: Diet Coke, Renowned Chef, Pop-Up Kitchen Reveal Secrets to Great Taste, Living Well 4
(Date:8/29/2014)... 2014 According to a ... Extraction type (SFE, Cold Pressed, Organic Solvent, & Others), ... Food Supplements, Fragrance, & Others) - Global Trends & ... segments the Amaranth Seed Oil Market with an ... terms of value. The Amaranth Seed Oil Market ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... 5, 2011 Today Scios Inc. announced an agreement with ... misbranding of NATRECOR® (nesiritide), a prescription medication for patients with ... Scios Inc. entered a guilty plea to a single misdemeanor ... to pay an $85 million fine. Scios acknowledges ...
... Puma Biotechnology, Inc., a development stage biopharmaceutical company, ... the worldwide commercial rights to neratinib, a potent, ... through the epidermal growth factor receptors, ErbB1 (EGFR), ... being studied in the neoadjuvant, adjuvant and metastatic ...
Cached Medicine Technology:Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 2Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 3Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 4Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 5